PD-1 Inhibitor
26 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05340270) | Guangxi Medical University | 2022-07-15 |
| Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer (NCT05401279) | RenJi Hospital | 2022-06-01 |
| G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT05222009) | Sun Yat-sen University | 2022-01-24 |
| Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. (NCT05615142) | Sichuan University | 2021-12-15 |
| Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma (NCT05048017) | Peking Union Medical College Hospital | 2021-10-01 |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma (NCT06333561) | Sun Yat-sen University | 2021-01-01 |
Track PD-1 Inhibitor automatically
Every clearance here is in the API, with alerts when new ones post.